Table 4 Univariate predictors of mortality and MACCE; rows in bold denote significance (p < 0.05)

Male sex

0.87 (0.28 - 2.70)

0.811

1.03 (0.38 - 2.79)

0.952

ACHD complexity

1.22 (0.54 - 2.72)

0.632

1.52 (0.75 - 3.09)

0.246

Single ventricle circulation

1.24 (0.33 - 4.62)

0.748

6.02 (1.23 - 29.37)

0.011

Prior cardiac surgery

5.53 (0.67 - 45.81)

0.054

1.985 (0.62 - 6.34)

0.246

Number of fluoroscopic procedures

1.02 (0.74 - 1.40)

0.928

1.46 (1.04 - 2.06)

0.018

History of arrhythmia

3.82 (1.15 - 12.67)

0.028

2.90 (1.02 - 8.17)

0.039

Systemic ventricular dysfunction at baseline

2.5 (0.49 - 12.76)

0.271

13.33 (0.73 - 247.15)^a

0.081

Subpulmonary ventricular dysfunction at baseline

0.56 (0.06 - 5.37)

0.601

6.63 (0.73 - 60.22)

0.093

Valvular dysfunction (> mild)

1.25 (0.38 - 4.11)

0.713

1.21 (0.42 - 3.47)

0.724

NYHA class at baseline

1.81 (0.65 - 5.09)

0.259

2.25 (0.71 - 7.09)

0.168

ACE-I/ARB use at baseline

1.06 (0.29 - 3.89)

0.935

1.15 (0.360 - 3.67)

0.814

Diuretic use at baseline

3.54 (1.04 - 12.04)

0.044

15.62 (1.91 - 127.64)

0.001

Beta blocker use at baseline

1.07 (0.33 - 3.42)

0.914

2.87 (0.94 - 8.66)

0.055

Multiple Cancer diagnoses

0.68 (0.13 - 3.54)

0.640

2.0 (0.48 - 8.35)

0.326

Cancer stage at diagnosis

2.37 (1.32 - 4.25)

0.004

0.80 (0.51 - 1.25)

0.325

Any systemic cancer therapy use

2.38 (0.68 - 8.36)

0.160

1.03 (0.38 - 2.79)

0.952

Platinum based compounds

0.59 (0.11 - 3.00)

0.521

0.89 (0.25 - 3.18)

0.859

Kinase inhibitor

2.44 (0.67 - 8.95)

0.178

1.05. (0.30 - 3.65)

0.939

Immune Checkpoint Inhibitor use

11.36 (1.95 - 66.38)

0.004

1.39 (0.24 - 8.17)

0.713

Anthracycline use

1.27 (0.29 - 5.49)

0.753

0.63 (0.16 - 2.42)

0.501

Mediastinal radiation therapy

0.77 (0.19 - 3.16)

0.711

1.47 (0.44 - 4.90)

0.529